Your Article Summary
See Latest ArticlesMetabolic control probability in tumour subvolumes or how to guide tumour dose redistribution in non-small cell lung cancer (NSCLC): An exploratory clinical study
Radiotherapy and Oncology, 06/26/09
Petit SF et al. - A methodology was presented to derive relationships between FDG uptake, dose and metabolic control. Although no strong dose effect relation was demonstrated, mVCP decreased with increasing FDG uptake and tumour volume.
Related Articles
Lung cancer: a biologically different disease in women?
Women's Health, 10/30/09
Relevance Score: 73%
Oestrogen plus progestin and lung cancer in postmenopausal women (Womens Health Initiative trial): a post-hoc analysis of a randomised controlled trial
The Lancet, 10/12/09
Relevance Score: 72%
Haplotype and Cell Proliferation Analyses of Candidate Lung Cancer Susceptibility Genes on Chromosome 15q24-25.1
Cancer Research, 10/06/09
Relevance Score: 71%
Noninvasive detection of lung cancer by analysis of exhaled breath
BMC Cancer, 10/09/09
Relevance Score: 70%
African American lung cancer patients may have different response to new cancer-fighting drugs
EurekAlert, 10/08/09
Relevance Score: 70%
Today in Lung/Thoracic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Long-term results of the international adjuvant lung cancer trial evaluating adjuvant cisplatin-based chemotherapy in resected lung cancer
Journal of Clinical Oncology, 12/01/09
Phase II study of carboplatin combined with weekly docetaxel in patients with advanced non-small cell lung cancer
Cancer Chemotherapy and Pharmacology, 12/01/09
Radiofrequency ablation in the treatment of liver and lung tumors
Bulletin du Cancer, 12/01/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Long-term results of the international adjuvant lung cancer trial evaluating adjuvant cisplatin-based chemotherapy in resected lung cancer
Journal of Clinical Oncology, 12/01/09
Results of a phase II study of bortezomib in patients with relapsed or refractory indolent lymphoma
Blood, 12/01/09
Treatment of recurrent platinum-resistant ovarian cancer with pegylated liposomal doxorubicin ; An evaluation of the therapeutic index with special emphasis on cardiac toxicity
Chemotherapy, 12/01/09